Could Alzheimer’s disease one day be detected with a simple blood test instead of expensive brain scans? In this episode of the TrialSite News Farago Podcast, we speak with John Dwyer, President and CEO of the Global Alzheimer’s Platform Foundation (GAP), about the Bio-Hermes-002 study and the future of Alzheimer’s detection. The conversation explores how researchers are evaluating blood biomarkers, genetics, cognitive testing, and digital biomarkers alongside MRI and PET imaging to better understand how Alzheimer’s may be identified earlier and more accessibly. Importantly, Bio-Hermes-002 is an observational study. No study drug is being tested. Instead, the goal is to improve how researchers and clinicians detect and screen for Alzheimer’s disease.
Topics discussed include:
• What blood biomarkers for Alzheimer’s can and cannot currently tell us
• The rise of digital biomarkers and digital cognitive assessments
• Why GAP partnered with Siemens Healthineers
• Why diversity matters in biomarker research
• Ethical questions surrounding early biological detection
• The emotional reality of Alzheimer’s disease
• Whether medicine and society are prepared for earlier diagnosis The episode also highlights the broader work of GAP and its partnerships aimed at accelerating and improving Alzheimer’s clinical research.